Beam Therapeutics Stock Price, News & Analysis (NASDAQ:BEAM) $29.40 +1.15 (+4.07%) (As of 02:34 PM ET) Add Compare Share Share Today's Range$28.27▼$29.8650-Day Range$17.69▼$30.7652-Week Range$16.95▼$51.60Volume471,226 shsAverage Volume986,953 shsMarket Capitalization$2.40 billionP/E RatioN/ADividend YieldN/APrice Target$48.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Beam Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.45 Rating ScoreUpside/Downside67.2% Upside$48.80 Price TargetShort InterestBearish16.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 2 Articles This WeekInsider TradingSelling Shares$73,343 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.85) to ($4.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector474th out of 949 stocksBiological Products, Except Diagnostic Industry71st out of 146 stocks 4.2 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 5 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.80, Beam Therapeutics has a forecasted upside of 67.2% from its current price of $29.19.Amount of Analyst CoverageBeam Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.97% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently decreased by 4.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 2.6 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows4 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,343.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions80.64% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.85) to ($4.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Beam Therapeutics Stock (NASDAQ:BEAM)Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesDecember 4, 2023 | markets.businessinsider.comBuy Rating Affirmed on Sana Biotechnology Amid Promising ARDENT Trial Results for SC291 TherapyNovember 30, 2023 | seekingalpha.comCRISPR Gene Editing: Beam TherapeuticsDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 23, 2023 | finance.yahoo.comBeam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 SharesNovember 20, 2023 | msn.comThe 3 Best Gene Editing Stocks on the Frontier of MedicineNovember 20, 2023 | markets.businessinsider.comPlus Therapeutics Announces Positive Results From ReSPECT-GBM Phase 2 StudyNovember 18, 2023 | finance.yahoo.comIs Beam Therapeutics Stock a Buy Now?November 17, 2023 | finance.yahoo.comWhat Makes Beam Therapeutics Inc. (BEAM) a New Buy StockDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 16, 2023 | msn.comVerve Therapeutics: Why Great Results Aren't EnoughNovember 13, 2023 | msn.comVerve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatmentNovember 10, 2023 | markets.businessinsider.comHold Rating on Beam Therapeutics: Evaluating Future Prospects, Financial Stability, and Recent Strategic MovesNovember 10, 2023 | finance.yahoo.comDoes Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?November 9, 2023 | finance.yahoo.comBeam Therapeutics (BEAM) Q3 Earnings & Revenues Beat EstimatesNovember 8, 2023 | msn.comBeam Therapeutics GAAP EPS of -$1.22 beats by $0.03, revenue of $17.19M misses by $6.7MNovember 7, 2023 | marketwatch.comVerve Therapeutics Shares Jump 29% on Higher 3Q RevenueNovember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Castle Biosciences (CSTL) and Kura Oncology (KURA)November 6, 2023 | markets.businessinsider.comPositive Market Trends and Innovative Gene Editing Technology Drive Buy Rating for Beam TherapeuticsNovember 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Beam Therapeutics (BEAM) and Argenx Se (ARGX)November 2, 2023 | finance.yahoo.comLilly buys out Beam in heart drug alliance with VerveOctober 31, 2023 | msn.comEli Lilly Purchases Rights for Gene-Editing Treatments from Beam TherapeuticsOctober 31, 2023 | bizjournals.comBeam sells opt-in rights to Eli Lilly for up to $600MOctober 31, 2023 | finance.yahoo.comAfter Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?October 31, 2023 | finance.yahoo.comWill CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should KnowOctober 31, 2023 | msn.comLilly to Pay Beam Up to $600 Million for DNA-Editing TherapiesOctober 31, 2023 | finance.yahoo.comBeam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular DiseaseOctober 30, 2023 | msn.comWith 1 Roadblock Down, Is Verve Therapeutics a Buy Now?See More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees439Year Founded2017Price Target and Rating Average Stock Price Target$48.80 High Stock Price Target$105.00 Low Stock Price Target$20.00 Potential Upside/Downside+72.7%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-289,090,000.00 Net Margins-384.62% Pretax Margin-383.39% Return on Equity-40.66% Return on Assets-23.59% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual Sales$60.92 million Price / Sales37.79 Cash FlowN/A Price / Cash FlowN/A Book Value$10.41 per share Price / Book2.71Miscellaneous Outstanding Shares81,500,000Free Float77,918,000Market Cap$2.30 billion OptionableNot Optionable Beta1.69 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 45)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 54)President Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 46)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsImmunityBioNASDAQ:IBRXDenali TherapeuticsNASDAQ:DNLIImmunocoreNASDAQ:IMCRArcellxNASDAQ:ACLXNeumora TherapeuticsNASDAQ:NMRAView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 34,770 shares on 11/30/2023Ownership: 0.043%Deutsche Bank AGBought 4,381 shares on 11/24/2023Ownership: 0.070%Walleye Trading LLCSold 2,300 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCBought 5,300 shares on 11/21/2023Ownership: 0.000%Penserra Capital Management LLCBought 2,793 shares on 11/16/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions BEAM Stock Analysis - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price target for 2024? 11 brokerages have issued twelve-month target prices for Beam Therapeutics' shares. Their BEAM share price targets range from $20.00 to $105.00. On average, they expect the company's stock price to reach $48.80 in the next year. This suggests a possible upside of 67.2% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2023? Beam Therapeutics' stock was trading at $39.11 at the start of the year. Since then, BEAM stock has decreased by 25.4% and is now trading at $29.19. View the best growth stocks for 2023 here. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) issued its earnings results on Wednesday, November, 8th. The company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm earned $17.20 million during the quarter, compared to analysts' expectations of $17.09 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 40.66% and a negative net margin of 384.62%. Beam Therapeutics's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.56) EPS. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.09%), FMR LLC (7.97%), Sumitomo Mitsui Trust Holdings Inc. (2.07%), Redmile Group LLC (1.80%), Baillie Gifford & Co. (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More This page (NASDAQ:BEAM) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.